X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NATCO PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NATCO PHARMA DISHMAN PHARMA/
NATCO PHARMA
 
P/E (TTM) x 25.1 16.1 155.6% View Chart
P/BV x 3.3 17.4 19.3% View Chart
Dividend Yield % 0.7 0.7 100.9%  

Financials

 DISHMAN PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NATCO PHARMA
Mar-14
DISHMAN PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs374877 42.7%   
Low Rs129424 30.4%   
Sales per share (Unadj.) Rs197.8223.4 88.5%  
Earnings per share (Unadj.) Rs21.231.1 68.3%  
Cash flow per share (Unadj.) Rs34.740.3 86.2%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.80.8 103.4%  
Book value per share (Unadj.) Rs179.9219.5 82.0%  
Shares outstanding (eoy) m80.6933.07 244.0%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x1.32.9 43.7%   
Avg P/E ratio x11.920.9 56.7%  
P/CF ratio (eoy) x7.216.1 44.9%  
Price / Book Value ratio x1.43.0 47.2%  
Dividend payout %9.416.1 58.6%   
Avg Mkt Cap Rs m20,30621,504 94.4%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3551,128 474.9%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,9617,389 216.0%  
Other income Rs m265167 158.8%   
Total revenues Rs m16,2267,556 214.7%   
Gross profit Rs m4,1031,793 228.8%  
Depreciation Rs m1,091304 358.3%   
Interest Rs m944366 257.9%   
Profit before tax Rs m2,3341,290 180.9%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624309 202.0%   
Profit after tax Rs m1,7111,027 166.5%  
Gross profit margin %25.724.3 105.9%  
Effective tax rate %26.723.9 111.7%   
Net profit margin %10.713.9 77.1%  
BALANCE SHEET DATA
Current assets Rs m11,0183,681 299.3%   
Current liabilities Rs m9,5173,123 304.8%   
Net working cap to sales %9.47.6 124.4%  
Current ratio x1.21.2 98.2%  
Inventory Days Days11089 123.5%  
Debtors Days Days3559 59.4%  
Net fixed assets Rs m16,3047,685 212.1%   
Share capital Rs m161331 48.8%   
"Free" reserves Rs m12,9076,670 193.5%   
Net worth Rs m14,5167,259 200.0%   
Long term debt Rs m4,189955 438.7%   
Total assets Rs m29,80511,957 249.3%  
Interest coverage x3.54.5 76.8%   
Debt to equity ratio x0.30.1 219.4%  
Sales to assets ratio x0.50.6 86.7%   
Return on assets %8.911.7 76.4%  
Return on equity %11.814.2 83.3%  
Return on capital %17.520.7 84.6%  
Exports to sales %24.839.4 63.0%   
Imports to sales %3.75.7 65.5%   
Exports (fob) Rs m3,9562,908 136.1%   
Imports (cif) Rs m596421 141.6%   
Fx inflow Rs m4,9523,445 143.7%   
Fx outflow Rs m697703 99.1%   
Net fx Rs m4,2552,743 155.1%   
CASH FLOW
From Operations Rs m2,7861,440 193.5%  
From Investments Rs m-1,529-1,089 140.4%  
From Financial Activity Rs m-941-353 266.8%  
Net Cashflow Rs m316-1 -21,234.9%  

Share Holding

Indian Promoters % 61.4 52.0 118.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 3.7 7.8 47.2%  
FIIs % 12.7 16.6 76.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 26.0 85.0%  
Shareholders   46,261 25,395 182.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  CIPLA  ABBOTT INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - AJANTA PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS